Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

[1]  G. Hortobagyi,et al.  Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial , 2021, Clinical Cancer Research.

[2]  F. Puglisi,et al.  292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial , 2021, Annals of Oncology.

[3]  M. Benelli,et al.  Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer , 2021, Cancers.

[4]  M. Benelli,et al.  CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. , 2020, Cancer treatment reviews.

[5]  Carolyn Allen,et al.  Thymidine kinase 1 through the ages: a comprehensive review , 2020, Cell & bioscience.

[6]  F. Bidard,et al.  Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy , 2020, Breast cancer research : BCR.

[7]  P. Bendahl,et al.  Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer , 2020, Scientific Reports.

[8]  A. Bardia,et al.  Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future , 2020, The Lancet.

[9]  G. Curigliano,et al.  Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial , 2020, Clinical Cancer Research.

[10]  M. Piccart,et al.  Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). , 2019, European journal of cancer.

[11]  R. Schiff,et al.  Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer , 2018, npj Breast Cancer.

[12]  L Biganzoli,et al.  Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Pestrin,et al.  Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy , 2018, Oncotarget.

[15]  M. Koehler,et al.  Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer , 2018, Nature Communications.

[16]  M. Ellis,et al.  Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib , 2017, Breast Cancer Research.

[17]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Zachary L. Skidmore,et al.  NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer , 2017, Clinical Cancer Research.

[19]  S. Loi,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[20]  C Sotiriou,et al.  The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.

[21]  Christos Sotiriou,et al.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Fernö,et al.  Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial , 2013, Breast Cancer Research and Treatment.

[23]  R. Robison,et al.  Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor Formation , 2012, Journal of oncology.

[24]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[25]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[26]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[27]  B Asselain,et al.  Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Blamey,et al.  Thymidine kinase in breast cancer. , 1990, British Journal of Cancer.

[29]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.